Fact Meets Function

A biocompatible polydopamine platform for targeted delivery of nicotinamide mononucleotide and boosting NAD+ levels in the brain.

Research Summary

This animal model study investigated a polydopamine-based delivery system designed to transport nicotinamide mononucleotide (NMN) across the blood-brain barrier and increase NAD+ levels in brain tissue. The researchers developed and tested this biocompatible nanoplatform in animal models and found that the delivery system successfully enhanced NAD+ accumulation in the brain compared to unformulated NMN. This work represents early-stage research demonstrating a potential mechanism for improving brain bioavailability of NMN through nanotechnology-based delivery approaches.

A biocompatible polydopamine platform for targeted delivery of nicotinamide mononucleotide and boosting NAD+ levels in the brain. Read Post »

New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.

This review article examines research on stable gastric pentadecapeptide (BPC-157), exploring its potential mechanisms in counteracting vascular dysfunction and multiorgan failure associated with occlusion/occlusion-like syndromes through cytoprotective and organoprotective pathways. The review synthesizes findings on how BPC-157 may interact with gastrointestinal protection mechanisms, though specific quantitative outcomes are not detailed in the available information. This is a review article synthesizing existing literature rather than original human clinical or animal research.

New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Read Post »

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

This pilot study examined the effects of BPC-157, a synthetic peptide derived from gastric juice, on symptoms in patients with interstitial cystitis (IC). The findings and specific outcomes are not detailed in the information provided, though pilot studies typically involve small patient populations and serve as preliminary investigations before larger trials. This research represents human clinical evidence, though pilot studies have inherent limitations including small sample sizes and lack of control groups.

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Read Post »

Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine.

This study examined whether hydromethylthionine (a tau aggregation inhibitor related to methylene blue) could restore glutamate release deficits in tau transgenic mice, finding that the compound successfully rescued synaptosomal glutamate release impairments associated with tau pathology. The research demonstrates a mechanistic link between tau aggregation and synaptic glutamate dysfunction in a mouse model of tauopathy. *Evidence level: Animal model* (Note: The source listed this as “Human Clinical,” but the actual study design employed tau transgenic mice, making this an animal model investigation).

Rescue of synaptosomal glutamate release defects in tau transgenic mice by the tau aggregation inhibitor hydromethylthionine. Read Post »

The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.

This human clinical study investigated how the glycyl-L-histidyl-L-lysine-Cu(2+) (GHK-Cu) tripeptide complex affects lung inflammation and fibrosis in silicosis by examining its interaction with peroxiredoxin 6. The researchers found that GHK-Cu attenuated both inflammatory and fibrotic responses in silicosis through a mechanism involving peroxiredoxin 6 as a molecular target. This evidence comes from human clinical research, representing the highest level of evidence for translational application to silicosis management.

The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6. Read Post »

Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.

This review article examines research on Stable Gastric Pentadecapeptide BPC 157 and its potential effects on intestinal anastomoses (surgical connections between bowel segments) based primarily on rat studies. The reviewed evidence suggests BPC 157 may influence intestinal healing processes, vascular responses, and tissue repair mechanisms at the anastomotic site in animal models. **Evidence level: Animal model and in vitro studies** with supporting mechanistic research, though the review synthesizes preclinical findings rather than presenting new clinical trial data in humans.

Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Read Post »

Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner.

This study examined the long-term effects of nicotinamide mononucleotide (NMN) supplementation on lifespan and healthspan in mice, finding that NMN treatment extended both measures, though the effects differed between male and female mice (animal model evidence). The sex-dependent response suggests that biological sex influences how organisms respond to NMN supplementation at the systemic level.

**Evidence level:** Animal model (mouse study)

Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner. Read Post »

Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications.

This review article examined nicotinamide mononucleotide (NMN) supplementation and the metabolic variability observed in response to NMN treatment across different populations and conditions. The review found that individual differences in NAD+ metabolism, age, genetic factors, and baseline metabolic status significantly influence how people respond to NMN supplementation, with implications for personalizing potential therapeutic applications. **Evidence level: Review article** (synthesizes existing literature rather than presenting original human clinical or experimental data).

Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications. Read Post »

Scroll to Top